Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01836354 · ClinicalTrials.gov registry record · NA

Discharge Educational Strategies for Reduction of Vascular Events

A NA study of Ischemic Stroke and Hemorrhagic Strokes, sponsored by NYU Langone Health.

Completed
Registry status
NA
Development phase
552
Enrollment target
3
Study locations

NCT01836354: Completed NA study of Ischemic Stroke and Hemorrhagic Strokes, sponsored by NYU Langone Health.

NCT01836354 is a NA study of Ischemic Stroke and Hemorrhagic Strokes that has completed, run by NYU Langone Health. The registered enrollment target is 552 participants, below the 1,455-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (62% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01836354, a NA study of Ischemic Stroke and Hemorrhagic Strokes, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
NA
Development phase
552 participants
Enrollment target
3
Study locations

Study Summary

DESERVE is a discharge education study using health workers to enroll and randomly assign 800 subjects diagnosed with TIA, or mild stroke to either risk factor education or usual care. Those patients assigned to education will receive stroke preparedness education plus risk factor reduction education, and help accessing follow up care with health workers. Those patients assigned to usual care will receive written stroke preparedness education. This protocol will evaluate the effectiveness of this intervention to reduce blood pressure, and individual stroke risk factors and future stroke risk.

Primary Outcome

change in overall blood pressure

Interventions

  • BEHAVIORAL DESERVE education

Study Locations (3)

New York

  • NYU Langone Medical Center - New York
  • Icahn School of Medicine at Mount Sinai - New York
  • Columbia University - New York

Trial Details

FieldValue
Enrollment Target 552 participants
Start Date 2012-08
Est. Completion 2019-11
Phase NA
NYU Langone Health

1,164 total trials

What the finished NCT01836354 record still lists

NCT01836354 is an interventional study that assigns participants to a tested intervention. The registered 552 participants enrollment target is mid-sized for trials with a published cap, below the 1,455-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (62% lower).

The record links to 4 conditions, with Ischemic Stroke appearing as the primary indexed condition, and to 1 intervention - of which DESERVE education is the first listed.

NCT01836354 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT01836354 about?

NCT01836354 is a clinical study titled "Discharge Educational Strategies for Reduction of Vascular Events". DESERVE is a discharge education study using health workers to enroll and randomly assign 800 subjects diagnosed with TIA, or mild stroke to either risk factor education or usual care. Those patients assigned to education will receive stroke preparedness education plus risk factor reduction educatio...

What is the current status of trial NCT01836354?

This trial is currently completed. It is a NA study. The enrollment target is 552 participants. The study started on 2012-08. Estimated completion is 2019-11.

What conditions does trial NCT01836354 study?

This clinical trial studies the following conditions: Ischemic Stroke, Hemorrhagic Strokes, Intracerebral Infarcts, TIA's.

What interventions are being tested in trial NCT01836354?

The interventions under investigation include: DESERVE education (BEHAVIORAL).

Who is sponsoring clinical trial NCT01836354?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01836354 being conducted?

This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ischemic Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01836354's enrollment target sits among peer trials

552 15th of 66 higher than 52 of 66 other Ischemic Stroke trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ischemic Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06217809 · 552 participants · NA

    EmpowHer is Prevention Curriculum for Youth Ages 10-15 Years.

  • NCT07146022 · 552 participants · Phase 3

    Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)

  • NCT05786924 · 554 participants · Phase 1

    Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  • NCT01852448 · 550 participants

    Genetics of Insulin and Incretins in Cystic Fibrosis

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01836354, the US trial registry maintained by the National Library of Medicine. NCT01836354 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.